Loxo Oncology Inc Logo Image

Loxo Oncology Inc

Most Recent Annual Report

2017 Annual Report and Form 10K

Loxo Oncology Inc

Loxo Oncology Inc has reached its limit for free report views.

Loxo Oncology Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

  • Loxo Oncology Inc
  • Loxo Oncology Inc
  • Loxo Oncology Inc

About Loxo Oncology Inc

11-50 Employees
Based in Stamford, Connecticut

Loxo Oncology, Inc. engages in the discovery, development, and commercialization of cancer therapies in the United States. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase (TRK), which is in a Phase I dose escalation trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol